Thrombosis
From the Journals
Direct oral anticoagulants: Competition brought no cost relief
Medicare Part D spending since 2011 has far outpaced growth in the use of oral anticoagulants.
From the Journals
Five risk factors may predict thrombus on LAA occlusion implants
With a new clinical risk score, patients deemed at high risk showed a twofold increased rate of this worrisome complication.
From the Journals
DOACs linked to lower mortality than vitamin K antagonist: 3-year TAVR registry
Mortality and bleeding advantage favors DOACs over VKA in TAVR patients who are candidates for anticoagulation.
From the Journals
Reversal agents curb DOAC-related bleeding but deaths still high
The meta-analysis of more than 4,000 patients also showed thrombotic events were more frequent with andexanet than with 4PCC or idarucizumab.
From the Journals
Are left atrial thrombi that defy preprocedure anticoagulation predictable?
Features that predispose to such persistent LA thrombi, which are not very rare, could potentially guide more targeted TEE screening before rhythm...
Conference Coverage
Single subcutaneous shot offers fast, potent platelet inhibition in STEMI
The effect was seen within 15 minutes of receiving RUC-4, an investigational glycoprotein IIb/IIIa inhibitor, with no thrombocytopenia, in a phase...
Guidelines
New AHA/ASA guideline on secondary stroke prevention
Identifying the cause of a first stroke or transient ischemic attack is key to developing strategies to prevent repeat events, the AHA/ASA says in...
News
FDA approves new treatment option for rare anemia
Pegcetacoplan (Empaveli) was approved as a treatment for paroxysmal nocturnal hemoglobinuria (PNH).
Conference Coverage
ADAPTABLE: Low-dose aspirin as good as high-dose in CHD?
A large randomized trial specifically designed to investigate the optimum dose of aspirin in patients with established coronary disease has found...
From the Journals
High teen BMI linked to stroke risk in young adulthood
Finding holds true for men and women, even for those individuals with BMIs in the high-normal range.
Conference Coverage
Cushing’s death rate ‘unacceptable,’ triple that of general population
Death rates among patients with endogenous Cushing’s syndrome have dropped since 2000 but are still threefold that of the general population.